Capstone Therapeutics Corp banner

Company Overview

Business Description

Sector
Health Care
Industry
Biotechnology
Headquarters
United States of America US
IPO date
Feb 4, 1993

Capstone Therapeutics Corp. is a biotechnology company. The company is headquartered in Tempe, Arizona. The firm is focused on development and commercialization of Apo E mimetic peptide AEM-28-14, through its investment in LipimetiX Development LLC. Apolipoprotein E is a 299 amino acid protein, which plays an important role in lipoprotein metabolism. AEM-28 is a 28 amino acid mimetic of Apo E and AEM-28-14, an analog of AEM-28, is a 28 amino acid mimetic of Apo E with an amino-hexanoic acid group and a phospholipid and both contain a domain, which anchors into a lipoprotein surface while also providing the Apo E receptor binding domain, which allows clearance through the heparan sulfate proteoglycan (HSPG) receptors in the liver. AEM-28-14 as an Apo E mimetic, has the potential to enhance the clearance of triglyceride- and cholesterol-rich lipoproteins from the plasma.

Capstone Therapeutics Corp Investor Relations

Address
1275 W Washington St Ste 101
Tempe, Arizona
United States of America

Management

Mr. Michael M. Toporek III

CEO, President & Chairman

Biography unavailable

Mr. Edward C. Schultz

VP, CFO & Treasurer

Biography unavailable

Mr. Matthew E. Lipman

VP, Secretary & Director

Biography unavailable

1 / 3